the combination of Anlotinib with Sintilimab as first-line treatment

Colorectal Cancer

Immunotherapy

Anlotinib

Sintilimab

Chemo-free Therapy

First-line Treatment

Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w

Anlotinib plus Sintilimab

Department of Medical Oncology, Shanghai Changzheng Hospital

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR): a Single Center, Single-arm Phase II Study (APICAL-CR)

Time from treatment beginning until disease progression

Time from treatment beginning until death from any cause

Investigation of depth of response during first-line treatment

Yuan-Sheng Zang

Director

Shanghai Changzheng Hospital

Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.

Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.

Recurrent Glioma (Glioblastoma Multiforme)

Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm

Radiation Therapy

Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm

Department of Radiotherapy, University Hospital Freiburg

Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme

Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial

Kaplan-Meier: Performed on the per protocol population - all patients who are eligible and have started their allocated treatment

Volumetrical assessment of delineated gross tumor volume (GTV) and planning target volume (PTV) based on AA-PET vs. delineated GTV/PTV based on T1-Gd-MRI.

papillon-lefevre disease/tyrosine

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)

Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum